This Online Education Activity is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for 1 European CME credit (ECMEC®). Welcome to the Update on HIV Treatment Options edition of the Online Meeting Highlights. Here you will learn about the safety profiles of Integrase inhibitors-based regimens, potential drug-drug interactions, and key considerations for future monitoring studies.
A new edition of the Online Meeting Highlights series is available now, providing an update on HIV treatment options.
Highly potent and well-tolerated antiretrovirals have transformed HIV into a mostly manageable condition. Integrase inhibitors-based regimens are currently preferred first-line options. Effective and affordable, those drugs also have a high barrier to resistance. Follow this edition and learn more about their safety profiles, potential drug-drug interactions, and key considerations for future monitoring studies.
Compromised adherence, associated in part with a daily pill burden, remains a major obstacle to effective antiretroviral therapy. Designed to tackle this issue, long-acting injectable drugs are opening a new era in HIV prevention and treatment. Find out here about the latest clinical developments and future prospects. Whether these novel drug modalities may offer an alternative solution to a vaccine, and strengthen infection control far beyond HIV that is much needed nowadays?
All modules can be followed independently and at your own pace. Complete the entire course to equip yourself with the knowledge to work towards making a significant impact on the survival and quality of life of your patients faced with these specific circumstances.
After following this eLearning activity, you will be able to:
- Interpret clinical data on injectable drug formulations for the prevention and treatment of HIV;
- Understand pharmacological properties, safety profile, and potential drug-drug interactions of integrase inhibitors; and
- Evaluate the optimal choice of generic versus branded antiretroviral drugs.
To obtain your certificate, you have complete all three modules, passed the relevant assessments and answered the evaluation survey.
Module 1 | Injectable Drugs for HIV Treatment
Module 2 | Update on INSTI Clinical Pharmacology
Module 3 | Considerations in the Use of Generic vs. Branded ARVs
Duration: approximately 20 minutes per module
You can enhance your learning experience by:
- adding notes to the video modules;
- consulting the accompanying presentation slides;
- sharing your questions and observations with other learners in the discussion board; and
- referring to further literature and other materials provided to you by our experts.
The program is aimed at clinicians from various specialties who occasionally treat HIV patients, such as primary care physicians, family doctors, OBGYN, transgender healthcare clinicians, adolescent medicine professionals, and preventive medicine professionals, as well as public health workers and researchers engaged in HIV related disciplines at varying degrees.
